Copertina

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Christian M. Vonk, Emma L. Boertjes, Francois G. Kavelaars, Melissa Rijken, Jolinda M. L. Konijnenburg, Roxanne E. Cromwell, Bob Löwenberg, Tim Grob, Peter J. M. Valk
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	HemaSphere
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
di: Frank G. Rücker, et al.
Pubblicazione: (2024)

Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
di: Sibylle Cocciardi, et al.
Pubblicazione: (2025)

Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
di: Roger Mulet‐Lazaro, et al.
Pubblicazione: (2025)

Prognostic value of measurable residual disease in high‐risk MDS after intensive chemotherapy in HOVON‐SAKK studies
di: Coen R. Veenstra, et al.
Pubblicazione: (2026)

APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications
di: Francesco Mannelli, et al.
Pubblicazione: (2026)

IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation
di: Adrien Caillet, et al.
Pubblicazione: (2024)

Functional, biochemical, and clinical characterization of natural mutations affecting arginine residues in the heparin‐binding site of antithrombin
di: Rosa Cifuentes‐Riquelme, et al.
Pubblicazione: (2026)

Clonal hematopoiesis in AML long‐term survivors: Risk factors and clinical consequences
di: Simon M. Krauß, et al.
Pubblicazione: (2025)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
di: Henri C. Hupe, et al.
Pubblicazione: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
di: Jan‐Niklas Eckardt, et al.
Pubblicazione: (2025)

From hypoxia single‐cell gene signatures to HIF targeting of AML leukemic stem cells
di: Thomas Mercher, et al.
Pubblicazione: (2024)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
di: Uwe Platzbecker, et al.
Pubblicazione: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
di: David A. Sallman, et al.
Pubblicazione: (2025)

Posttransplantation clonal dynamics of hematopoietic stem cells carrying prenatal and early‐life DNMT3A mutations
di: Lucca L. M. Derks, et al.
Pubblicazione: (2025)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
di: Sophia Stock, et al.
Pubblicazione: (2025)

PRC2‐mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7
di: Hiroyoshi Kunimoto, et al.
Pubblicazione: (2025)

Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy)
di: Martijn P. T. Ernst, et al.
Pubblicazione: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
di: Konstanze Döhner, et al.
Pubblicazione: (2025)

Rps19 R67∆ mutation creates a model of Diamond–Blackfan anemia and reveals downstream mediators of p53 pathway
di: Juraj Kokavec, et al.
Pubblicazione: (2026)

Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
di: Romain Stammler, et al.
Pubblicazione: (2025)

Response to therapy and prognosis according to molecular characterization in CALR ‐mutated essential thrombocythemia
di: Marta Santaliestra, et al.
Pubblicazione: (2026)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
di: Suzana da Silva‐Benedito, et al.
Pubblicazione: (2026)

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
di: Aida Santaolalla, et al.
Pubblicazione: (2026)

Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
di: Sarka Pavlova, et al.
Pubblicazione: (2025)

Immunophenotypic abnormality quantification refines multiparameter flow cytometry‐based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission
di: Calvin M. Le, et al.
Pubblicazione: (2026)

The rearrangement partner and the presence of MYC mutations determine the outcome of patients with MYC and BCL6 rearrangements
di: Anna Stengel, et al.
Pubblicazione: (2026)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
di: Patrick Born, et al.
Pubblicazione: (2025)

Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
di: Shoshana Burke, et al.
Pubblicazione: (2025)

Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials
di: Celia González‐Gil, et al.
Pubblicazione: (2025)

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes
di: David Rombaut, et al.
Pubblicazione: (2025)

Integration of gene mutations in risk prognostication for watch‐and‐wait follicular lymphoma patients initiating first‐line treatment
di: Tian‐Yuan Xu, et al.
Pubblicazione: (2025)

Correction to “Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials”
Pubblicazione: (2026)

Correction to “Posttransplantation clonal dynamics of hematopoietic stem cells carrying prenatal and early‐life DNMT3A mutations”
Pubblicazione: (2026)

Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry
di: David F. Moreno, et al.
Pubblicazione: (2024)

Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A‐rearranged acute leukemia
di: Qirui Zhang, et al.
Pubblicazione: (2024)

Navigating the evolving management of smoldering multiple myeloma
di: M. Bakri Hammami, et al.
Pubblicazione: (2026)

Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy
di: Gunnar Cario, et al.
Pubblicazione: (2025)

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
di: Prashant R. Tembhare, et al.
Pubblicazione: (2024)

T‐cell lymphoblastic lymphoma in constitutional mismatch repair deficiency (CMMRD): Exploring treatment opportunities
di: Emma Kroeze, et al.
Pubblicazione: (2024)

Autologous stem cell transplantation in NK/T‐cell lymphoma: Prognostic impact of EBV‐DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party
di: Philipp Berning, et al.
Pubblicazione: (2025)